Blood

Investors show faith in Biopure

Investors show faith in Biopure

By Gregory Roumeliotis

Oxygen therapeutics company Biopure has announced another $3
million (€2.5 million) public offering to boost its working
capital, despite its major drug for humans, Hemopure, an artificial
blood product, being licensed only in South...

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers